A Cost-Effective Screening Inflammation Indicator for Atopic Dermatitis Suitable for Primary Care and Self-Assessment

Area of Science:

• Biomarker development
• Dermatology
• Inflammatory diseases

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition impacting quality of life and often underdiagnosed in primary care.
• Existing blood-cell-derived inflammatory indices have limited pathological relevance to AD.
• Novel, cost-effective biomarkers are needed for AD diagnosis and management.

Purpose of the Study:

• To develop and validate a novel blood-cell-based biomarker, the Atopic Inflammation Index (AII), for atopic dermatitis (AD).
• To assess AII's diagnostic performance compared to existing biomarkers like IgE and eosinophils.
• To evaluate AII's utility in primary care settings for screening and diagnosing AD.

Main Methods:

• Developed the Atopic Inflammation Index (AII) from blood cell counts.
• Assessed AII in clinical samples from AD patients and healthy controls.
• Analyzed NHANES 2005-2006 cohort data (n=6855) to verify AII-AD association and diagnostic performance against IgE and eosinophils.

Main Results:

• AII demonstrated a nonlinear association with AD severity and effectively distinguished AD patients from healthy controls (p < 0.001).
• AII levels were significantly higher in AD patients within the NHANES cohort (p = 0.007) and remained independently associated (OR = 1.03).
• AII outperformed eosinophils in diagnostic accuracy (AUC: 0.568 vs. 0.546, p = 0.025) with improved sensitivity.

Conclusions:

• The Atopic Inflammation Index (AII) is a stable and reliable biomarker for screening and diagnosing atopic dermatitis (AD).
• AII offers a low-cost, practical solution for AD detection in primary care settings.
• This study validates integrating existing indicators into new biomarkers, inspiring precision medicine research.